Isofol Medical AB Earnings Call Transcripts
Fiscal Year 2026
-
Arfolitixorin is advancing through Phase Ib dose escalation, with no dose-limiting toxicities reported and interim tumor shrinkage in all treated patients. Phase II is planned to compare two doses with standard care, while the U.S. colorectal cancer opportunity was estimated at $1 billion in potential gross sales.
-
Arfolitixorin, a next-generation folate, is being developed to address the high unmet need in metastatic colorectal cancer, with promising early clinical results and a large commercial opportunity. Ongoing trials are expanding across multiple countries, and market research supports strong pricing potential if efficacy is demonstrated.
Fiscal Year 2025
-
Multiple clinical and financial milestones have been achieved, including a successful rights issue, FDA and Japanese regulatory progress, and a new patent extending exclusivity to 2043. The ongoing phase 1B/2 study is advancing with higher, well-tolerated doses and an improved design, supporting strong commercial and scientific potential.
-
Exited the quarter with a strengthened financial position after an oversubscribed rights issue and continued progress in clinical trials. R&D expenses increased, resulting in a higher net loss, but positive regulatory feedback and new partnerships support future growth.